JAK2 V617F Mutation Detection: Laboratory Comparison of Two Kits Using RFLP and qPCR

被引:4
作者
Shammaa, Dina [1 ]
Bazarbachi, Ali [2 ]
Halas, Hussein [1 ]
Greige, Layal [1 ]
Mahfouz, Rami [1 ]
机构
[1] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, Beirut, Lebanon
[2] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon
关键词
MYELOPROLIFERATIVE-DISORDERS; POLYCYTHEMIA-VERA; TYROSINE KINASE; IDIOPATHIC MYELOFIBROSIS; ERYTHROPOIETIN; PROGENITORS; ACTIVATION; JAK2V617F; LEUKEMIA; SUBTYPES;
D O I
10.1089/gtmb.2009.0119
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aim: The JAK2 V617F mutation has been implicated in a variety of diseases mainly related to myeloproliferative disorders including polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis with an increased demand for testing using molecular techniques. The latter are diversified and all aim to simplify the methods employed for detection. Materials and Methods: In this study, two detection kits were compared: one using polymerase chain reaction (PCR)-restriction fragment length polymorphisms (RFLP) (JAK2 Activating Mutation assay; InVivoScribe Technologies, San Diego, CA) and the other using real-time quantitative PCR (JAK2 MutaScreen Kit assay; Ipsogen, Marseilles, France). Results: A total of 80 reactions were compared using the two techniques and the results showed a perfect concordance between the two methods. Conclusion: We conclude that both PCR-RFLP and quantitative PCR are extremely useful and sensitive techniques for the detection of the JAK2 V617F mutation with quantitative PCR being more time effective and less expensive.
引用
收藏
页码:13 / 15
页数:3
相关论文
共 18 条
  • [1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter, EJ
    Scott, LM
    Campbell, PJ
    East, C
    Fourouclas, N
    Swanton, S
    Vassiliou, GS
    Bench, AJ
    Boyd, EM
    Curtin, N
    Scott, MA
    Erber, WN
    Green, AR
    [J]. LANCET, 2005, 365 (9464) : 1054 - 1061
  • [2] V617F mutation in JAK2 is associated idiopathic myelofibrosis
    Campbell, PJ
    Griesshammer, M
    Döhner, K
    Döhner, H
    Kusec, R
    Hasselbalch, HC
    Larsen, TS
    Pallisgaard, N
    Giraudier, S
    Le Bousse-Kerdilès, MC
    Desterke, C
    Guerton, B
    Dupriez, B
    Bordessoule, D
    Fenaux, P
    Kiladjian, JJ
    Viallard, JF
    Brière, J
    Harrison, CN
    Green, AR
    Reilly, JT
    [J]. BLOOD, 2006, 107 (05) : 2098 - 2100
  • [3] Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
    Campbell, PJ
    Scott, LM
    Buck, G
    Wheatley, K
    East, CL
    Marsden, JT
    Duffy, A
    Boyd, EM
    Bench, AJ
    Scott, MA
    Vassiliou, GS
    Milligan, DW
    Smith, SR
    Erber, WN
    Bareford, D
    Wilkins, BS
    Reilly, JT
    Harrison, CN
    Green, AR
    [J]. LANCET, 2005, 366 (9501) : 1945 - 1953
  • [4] Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7
    Fröhling, S
    Lipka, DB
    Kayser, S
    Scholl, C
    Schlenk, RF
    Döhner, H
    Gilliland, DG
    Levine, RL
    Döhner, K
    [J]. BLOOD, 2006, 107 (03) : 1242 - 1243
  • [5] JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia
    Jelinek, J
    Oki, Y
    Gharibyan, V
    Bueso-Ramos, C
    Prchal, JT
    Verstovsek, S
    Beran, M
    Estey, E
    Kantarjian, HM
    Issa, JPJ
    [J]. BLOOD, 2005, 106 (10) : 3370 - 3373
  • [6] Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
    Jones, AV
    Kreil, S
    Zoi, K
    Waghorn, K
    Curtis, C
    Zhang, LY
    Score, J
    Seear, R
    Chase, AJ
    Grand, FH
    White, H
    Zoi, C
    Loukopoulos, D
    Terpos, E
    Vervessou, EC
    Schultheis, B
    Emig, M
    Ernst, T
    Lengfelder, E
    Hehlmann, R
    Hochhaus, A
    Oscier, D
    Silver, RT
    Reiter, A
    Cross, NCP
    [J]. BLOOD, 2005, 106 (06) : 2162 - 2168
  • [7] Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: Possible relationship with FKBP51 overexpression
    Komura, E
    Chagraoui, H
    de Mas, VM
    Blanchet, B
    de Sepulveda, P
    Larbret, F
    Larghero, J
    Tulliez, M
    Debili, N
    Vainchenker, W
    Giraudier, S
    [J]. EXPERIMENTAL HEMATOLOGY, 2003, 31 (07) : 622 - 630
  • [8] A gain-of-function mutation of JAK2 in myeloproliferative disorders
    Kralovics, R
    Passamonti, F
    Buser, AS
    Teo, S
    Tiedt, R
    Passweg, JR
    Tichelli, A
    Cazzola, M
    Skoda, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) : 1779 - 1790
  • [9] The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
    Levine, RL
    Loriaux, M
    Huntly, BJP
    Loh, ML
    Beran, M
    Stoffregen, E
    Berger, R
    Clark, JJ
    Willis, SG
    Nguyen, KT
    Flores, NJ
    Estey, E
    Gattermann, N
    Armstrong, S
    Look, AT
    Griffin, JD
    Bernard, OA
    Heinrich, MC
    Gilliland, DG
    Druker, B
    Deininger, MWN
    [J]. BLOOD, 2005, 106 (10) : 3377 - 3379
  • [10] X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and NIMM patients with clonal hematopoiesis
    Levine, Ross L.
    Belisle, Claude
    Wadleigh, Martha
    Zahrieh, David
    Lee, Stephanie
    Chagnon, Pierre
    Gilliland, D. Gary
    Busque, Lambert
    [J]. BLOOD, 2006, 107 (10) : 4139 - 4141